Cargando…
Comprehensive molecular biomarker identification in breast cancer brain metastases
BACKGROUND: Breast cancer brain metastases (BCBM) develop in about 20–30% of breast cancer (BC) patients. BCBM are associated with dismal prognosis not at least due to lack of valuable molecular therapeutic targets. The aim of the study was to identify new molecular biomarkers and targets in BCBM by...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5747948/ https://www.ncbi.nlm.nih.gov/pubmed/29287594 http://dx.doi.org/10.1186/s12967-017-1370-x |
_version_ | 1783289338809810944 |
---|---|
author | Schulten, Hans-Juergen Bangash, Mohammed Karim, Sajjad Dallol, Ashraf Hussein, Deema Merdad, Adnan Al-Thoubaity, Fatma K. Al-Maghrabi, Jaudah Jamal, Awatif Al-Ghamdi, Fahad Choudhry, Hani Baeesa, Saleh S. Chaudhary, Adeel G. Al-Qahtani, Mohammed H. |
author_facet | Schulten, Hans-Juergen Bangash, Mohammed Karim, Sajjad Dallol, Ashraf Hussein, Deema Merdad, Adnan Al-Thoubaity, Fatma K. Al-Maghrabi, Jaudah Jamal, Awatif Al-Ghamdi, Fahad Choudhry, Hani Baeesa, Saleh S. Chaudhary, Adeel G. Al-Qahtani, Mohammed H. |
author_sort | Schulten, Hans-Juergen |
collection | PubMed |
description | BACKGROUND: Breast cancer brain metastases (BCBM) develop in about 20–30% of breast cancer (BC) patients. BCBM are associated with dismal prognosis not at least due to lack of valuable molecular therapeutic targets. The aim of the study was to identify new molecular biomarkers and targets in BCBM by using complementary state-of-the-art techniques. METHODS: We compared array expression profiles of three BCBM with 16 non-brain metastatic BC and 16 primary brain tumors (prBT) using a false discovery rate (FDR) p < 0.05 and fold change (FC) > 2. Biofunctional analysis was conducted on the differentially expressed probe sets. High-density arrays were employed to detect copy number variations (CNVs) and whole exome sequencing (WES) with paired-end reads of 150 bp was utilized to detect gene mutations in the three BCBM. RESULTS: The top 370 probe sets that were differentially expressed between BCBM and both BC and prBT were in the majority comparably overexpressed in BCBM and included, e.g. the coding genes BCL3, BNIP3, BNIP3P1, BRIP1, CASP14, CDC25A, DMBT1, IDH2, E2F1, MYCN, RAD51, RAD54L, and VDR. A number of small nucleolar RNAs (snoRNAs) were comparably overexpressed in BCBM and included SNORA1, SNORA2A, SNORA9, SNORA10, SNORA22, SNORA24, SNORA30, SNORA37, SNORA38, SNORA52, SNORA71A, SNORA71B, SNORA71C, SNORD13P2, SNORD15A, SNORD34, SNORD35A, SNORD41, SNORD53, and SCARNA22. The top canonical pathway was entitled, role of BRCA1 in DNA damage response. Network analysis revealed key nodes as Akt, ERK1/2, NFkB, and Ras in a predicted activation stage. Downregulated genes in a data set that was shared between BCBM and prBT comprised, e.g. BC cell line invasion markers JUN, MMP3, TFF1, and HAS2. Important cancer genes affected by CNVs included TP53, BRCA1, BRCA2, ERBB2, IDH1, and IDH2. WES detected numerous mutations, some of which affecting BC associated genes as CDH1, HEPACAM, and LOXHD1. CONCLUSIONS: Using complementary molecular genetic techniques, this study identified shared and unshared molecular events in three highly aberrant BCBM emphasizing the challenge to detect new molecular biomarkers and targets with translational implications. Among new findings with the capacity to gain clinical relevance is the detection of overexpressed snoRNAs known to regulate some critical cellular functions as ribosome biogenesis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12967-017-1370-x) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5747948 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-57479482018-01-03 Comprehensive molecular biomarker identification in breast cancer brain metastases Schulten, Hans-Juergen Bangash, Mohammed Karim, Sajjad Dallol, Ashraf Hussein, Deema Merdad, Adnan Al-Thoubaity, Fatma K. Al-Maghrabi, Jaudah Jamal, Awatif Al-Ghamdi, Fahad Choudhry, Hani Baeesa, Saleh S. Chaudhary, Adeel G. Al-Qahtani, Mohammed H. J Transl Med Research BACKGROUND: Breast cancer brain metastases (BCBM) develop in about 20–30% of breast cancer (BC) patients. BCBM are associated with dismal prognosis not at least due to lack of valuable molecular therapeutic targets. The aim of the study was to identify new molecular biomarkers and targets in BCBM by using complementary state-of-the-art techniques. METHODS: We compared array expression profiles of three BCBM with 16 non-brain metastatic BC and 16 primary brain tumors (prBT) using a false discovery rate (FDR) p < 0.05 and fold change (FC) > 2. Biofunctional analysis was conducted on the differentially expressed probe sets. High-density arrays were employed to detect copy number variations (CNVs) and whole exome sequencing (WES) with paired-end reads of 150 bp was utilized to detect gene mutations in the three BCBM. RESULTS: The top 370 probe sets that were differentially expressed between BCBM and both BC and prBT were in the majority comparably overexpressed in BCBM and included, e.g. the coding genes BCL3, BNIP3, BNIP3P1, BRIP1, CASP14, CDC25A, DMBT1, IDH2, E2F1, MYCN, RAD51, RAD54L, and VDR. A number of small nucleolar RNAs (snoRNAs) were comparably overexpressed in BCBM and included SNORA1, SNORA2A, SNORA9, SNORA10, SNORA22, SNORA24, SNORA30, SNORA37, SNORA38, SNORA52, SNORA71A, SNORA71B, SNORA71C, SNORD13P2, SNORD15A, SNORD34, SNORD35A, SNORD41, SNORD53, and SCARNA22. The top canonical pathway was entitled, role of BRCA1 in DNA damage response. Network analysis revealed key nodes as Akt, ERK1/2, NFkB, and Ras in a predicted activation stage. Downregulated genes in a data set that was shared between BCBM and prBT comprised, e.g. BC cell line invasion markers JUN, MMP3, TFF1, and HAS2. Important cancer genes affected by CNVs included TP53, BRCA1, BRCA2, ERBB2, IDH1, and IDH2. WES detected numerous mutations, some of which affecting BC associated genes as CDH1, HEPACAM, and LOXHD1. CONCLUSIONS: Using complementary molecular genetic techniques, this study identified shared and unshared molecular events in three highly aberrant BCBM emphasizing the challenge to detect new molecular biomarkers and targets with translational implications. Among new findings with the capacity to gain clinical relevance is the detection of overexpressed snoRNAs known to regulate some critical cellular functions as ribosome biogenesis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12967-017-1370-x) contains supplementary material, which is available to authorized users. BioMed Central 2017-12-29 /pmc/articles/PMC5747948/ /pubmed/29287594 http://dx.doi.org/10.1186/s12967-017-1370-x Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Schulten, Hans-Juergen Bangash, Mohammed Karim, Sajjad Dallol, Ashraf Hussein, Deema Merdad, Adnan Al-Thoubaity, Fatma K. Al-Maghrabi, Jaudah Jamal, Awatif Al-Ghamdi, Fahad Choudhry, Hani Baeesa, Saleh S. Chaudhary, Adeel G. Al-Qahtani, Mohammed H. Comprehensive molecular biomarker identification in breast cancer brain metastases |
title | Comprehensive molecular biomarker identification in breast cancer brain metastases |
title_full | Comprehensive molecular biomarker identification in breast cancer brain metastases |
title_fullStr | Comprehensive molecular biomarker identification in breast cancer brain metastases |
title_full_unstemmed | Comprehensive molecular biomarker identification in breast cancer brain metastases |
title_short | Comprehensive molecular biomarker identification in breast cancer brain metastases |
title_sort | comprehensive molecular biomarker identification in breast cancer brain metastases |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5747948/ https://www.ncbi.nlm.nih.gov/pubmed/29287594 http://dx.doi.org/10.1186/s12967-017-1370-x |
work_keys_str_mv | AT schultenhansjuergen comprehensivemolecularbiomarkeridentificationinbreastcancerbrainmetastases AT bangashmohammed comprehensivemolecularbiomarkeridentificationinbreastcancerbrainmetastases AT karimsajjad comprehensivemolecularbiomarkeridentificationinbreastcancerbrainmetastases AT dallolashraf comprehensivemolecularbiomarkeridentificationinbreastcancerbrainmetastases AT husseindeema comprehensivemolecularbiomarkeridentificationinbreastcancerbrainmetastases AT merdadadnan comprehensivemolecularbiomarkeridentificationinbreastcancerbrainmetastases AT althoubaityfatmak comprehensivemolecularbiomarkeridentificationinbreastcancerbrainmetastases AT almaghrabijaudah comprehensivemolecularbiomarkeridentificationinbreastcancerbrainmetastases AT jamalawatif comprehensivemolecularbiomarkeridentificationinbreastcancerbrainmetastases AT alghamdifahad comprehensivemolecularbiomarkeridentificationinbreastcancerbrainmetastases AT choudhryhani comprehensivemolecularbiomarkeridentificationinbreastcancerbrainmetastases AT baeesasalehs comprehensivemolecularbiomarkeridentificationinbreastcancerbrainmetastases AT chaudharyadeelg comprehensivemolecularbiomarkeridentificationinbreastcancerbrainmetastases AT alqahtanimohammedh comprehensivemolecularbiomarkeridentificationinbreastcancerbrainmetastases |